Patients (May) Know Best: Leveraging the Patient Experience From Development to Commercialization

by Goodwin
Contact

Goodwin

Under the 21st Century Cures Act,[2] the FDA is required to develop guidance documents on how to collect and utilize patient experience data in drug development.[3] The agency has published a plan for the timing and focus of the required guidance documents, described below:

Due Date[4] Draft Guidance Title (or Topic)
End of FY 2018 Patient-Focused Drug Development: Collecting Comprehensive and Representative Input
End of FY 2019 Processes and methodological approaches to development of holistic sets of impacts that are most important to patients
End of FY 2020 Approaches to identifying and developing measures for an identified set of impacts (e.g., burden of disease and treatment), which may facilitate collection of meaningful patient input in clinical trials
End of FY 2021 Clinical outcome assessments, which, when final, will, as appropriate, revise or supplement the 2009 Guidance to Industry on Patient-Reported Outcome Measures

The FDA previously held a number of patient-focused drug development meetings, each focusing on a different disease area.[5] Through these meetings, the agency found that patients often are experts on the day-to-day effects of their disease, and “what patients care most about may not always be factored into clinical trials or approved labeling.”[6] As a result, the recently issued draft guidance is intended to provide drug developers with the FDA’s current thinking on steps they can begin taking to incorporate patient perspectives early in the drug development process and recommendations for discussing those plans with the FDA to ensure the usability of those data.  

The draft guidance, titled “Patient-Focused Drug Development: Collecting Comprehensive and Representative Input,” focuses on how to effectively define the patient population for collecting information and methods for collecting patient experience information, and contains a number of recommendations for industry.[7] In this client alert, we provide an overview of the draft guidance and its recommendations along with a snapshot of the commercial opportunity beyond informing drug development that patient experience data can serve. Lastly, we discuss the FDA’s upcoming two-day public workshop on October 15-16, 2018, during which the agency will gather feedback from stakeholders to help develop its next draft guidance on patient-focused drug development.

Background on Patient Experience Data

Patient experience data can be useful for designing clinical trials and selecting endpoints, and it can be used in submissions for regulatory review, including product labeling.[8] In the draft guidance, the FDA defines patient experience data as “data intended to provide information about patients’ experiences with a disease or condition, including the impact (including physical and psychosocial impacts) of a disease or condition, or a related therapy or clinical investigation on patients’ lives; and patient preferences with respect to treatment of their disease or condition.”[9] The draft guidance further explains that patient experience data includes patient perspectives and priorities related to the history of their condition and the impact of symptoms and treatments on their quality of life, as well as feelings and preferences that patients have related to the treatment of their disease.[10]

This description aligns with Section 3001 of the 21st Century Cures Act, which amended Section 569C of the Federal Food, Drug, and Cosmetic Act to define patient experience data as data that “(1) are collected by any persons (including patients, family members and caregivers of patients, patient advocacy organizations, disease research foundations, researchers, and drug manufacturers); and (2) are intended to provide information about patients’ experiences with a disease or condition, including—(A) the impact of such disease or condition, or a related therapy, on patients’ lives; and (B) patient preferences with respect to treatment of such disease or condition.”[11]

The FDA’s key recommendations to industry in its recent draft guidance include[12]:

Choosing a Patient Population

  • Consider the relationship between the research goals and methods of the proposed study when choosing a patient population from which to collect information.
  • Patients should report their experiences and preferences directly whenever possible.
  • Where necessary, data collected from patients may be supplemented with input from clinicians and other subject matter experts.
  • Have early discussions with the agency regarding how information about the patient population could inform medical product development and regulatory decisions in the future.
  • Research plans should seek to produce data that are not only representative of the target population, but also objective, relevant, and accurate.
  • Such a plan should consider socioeconomic, demographic, and cultural factors, as well as literacy and clinical characteristics of the intended patient population.

Study Design for Collecting Patient Experience Data

  • Consider the goals of collecting patient experience data, the target population and the availability of members of the target population, and what information is most relevant to answering the research questions, as well as budget and timing.
  • Be specific when defining research objectives and consulting previous research studies, literature in the field, and subject matter experts.
  • Collecting information from patients from a single site is discouraged; instead, studies should include patients from a diverse set of sites.
  • Adjust research objectives, as necessary, if sample size is limited due to practical limitations (e.g., the disease being studied is rare), and communicate this limitation in the data report.
  • Choose a method that will actively engage patients in the development process.
  • All researchers involved should receive standardized training and have defined roles outlined in the protocol to reduce potential site issues.

Recommended Sampling Methods

  • Consider research objectives when choosing a sampling scheme and consult with subject matter experts wherever possible.
  • Ensure that the sampling method will produce data that are representative of the target population; an appropriate sampling method is one that allows research questions to be answered within the constraints of the research study.
  • Such a method should include a well-defined target population, a clear list of the individual participants, and a mechanism for randomly selecting a sample.
  • Specific sampling methods include observations, interviews, questionnaires, and audiovisual and digital approaches.
  • With respect to questionnaires, all participants should be asked the same, pre-tested questions that address only one concept at a time and provided with distinct response options to facilitate understanding and avoid confusion.
  • If using audiovisual materials, obtain permission for use of materials and web content as well as informed consent.
  • Try using social media tools to collect information, but be mindful that certain tools are more appropriate for particular demographic groups, and that data collected in this way should adhere to standards to avoid potential limitations and ensure integrity of the data.
  • If using Digital Health Technology, discuss the proposed method early with the FDA to obtain feedback from the relevant division.

Analysis of Patient Experience Data

  • Once the patient experience data have been collected, align approaches for compiling, organizing, classifying, and interpreting the data with the research goals outlined in the protocol.
  • Anticipate that there may be missing data and plan accordingly by establishing strategies in the study design to minimize and understand missing data.
  • Provide a table summarizing missing data and establish steps in the protocol for handling missing data in the analysis.
  • Collaborate with others, such as clinicians and subject matter experts, and consult available registries and databases to utilize existing data where primary data may not be feasible, with the caveat that care should be taken to ensure the integrity of the data and the methods by which they were collected.
  • Establish a data management plan early in the study design process to standardize data collection and storage and provide a record of the planned research study.
  • Comply with appropriate data and regulatory standards even if the study is not conducted to support a regulatory medical product application or medical product labeling language because any clinical data eventually intended for submission will be subject to such standards.

Submission of Patient Experience Data to the FDA

  • When submitting patient experience data to the FDA, include a report and protocol from the research study, including information about data collection.
  • Discuss specific data collection criteria with the agency early in the study design process and explain the rationale for submitting patient experience data to obtain feedback related to the study protocol from the relevant division.
  • There are many existing FDA regulations and guidances that govern the collection and submission of clinical data, and those and other regulations (such as product labeling requirements) may apply to the submission of patient experience data.
  • Comply with all applicable laws and policies related to the use of patient information, informed consent, and IRB requirements, and conduct studies according to good clinical practice.
  • Additional information is forthcoming regarding the procedures for submitting patient experience data to the FDA.

A Commercial Benefit: Patient Experience Data in Drug Labeling

Patient experience data supporting a new drug or biologic approval can be especially important in the commercial stage, as drug manufacturers prepare marketing and advertising campaigns both for healthcare professionals and patients alike. In particular, having patient experience data included in FDA-approved drug labeling provides an FDA-approved means for talking directly to healthcare professionals and patients about data points and outcomes meaningful to them. Moreover, it gives the drug manufacturer or marketer the ability to promote approved drug products using the patient’s voice, which can be very impactful and resonate well with both physician and patient audiences.

A drug approval the FDA issued last summer highlights how patient experience data can be incorporated into product labeling and promotion.  In June 2017, the FDA approved Rituxan Hycela (rituximab/hyaluronidase human), a subcutaneously administered product indicated for the treatment of several oncologic conditions. The FDA had previously approved Rituxan® (rituximab), an intravenous product, for the same oncologic indications (as well as additional indications). The subcutaneous product is infused over 5-7 minutes, whereas the intravenous product is infused slowly, over 1.5-4+ hours.[13]

In a dedicated, open-label study conducted to support the development and approval of Rituxan Hycela, patients were assigned to receive either intravenous Rituxan or subcutaneous Rituxan Hycela (after one cycle of the intravenous product). After four cycles, the patients were crossed over to the alternative route of administration and asked to complete a questionnaire about their patient experience. Specifically, a Patient Preference Questionnaire asked three questions: (1) which route of administration the patient preferred; (2) how strong the preference was; and (3) the two main reasons for that preference. The sponsor submitted these data to the FDA for review and inclusion in its product labeling. As a result, Rituxan Hycela’s approved labeling includes a dedicated “Patient Experience” section that includes the sponsor’s patient preference findings, namely that 77% of patients studied preferred the subcutaneous dose, as well as the reasons patients provided for preferring the subcutaneous or intravenous administration.[14] The manufacturer then leveraged these data commercially, promoting that “Nearly 8 in 10 Patients Preferred” Rituxan Hycela to Rituxan administration—a claim that may have significant importance in a cancer patient population focused on quality of life concerns—and the patient experience data paved the way.[15]

Sponsors should not overlook the FDA’s willingness to include a dedicated “Patient Experience” section in approved product labeling, especially when developing research plans for new products in crowded treatment spaces or ones not well-understood by professionals or patients. We expect that designing patient experience studies with commercial utility, as with the example above, will become a routine part of drug development over time.

The Road Ahead

On August 13, 2018, the FDA announced[16] an upcoming two-day public workshop on the next phase of its patient-focused drug development initiative. The workshop will be held October 15-16, 2018 and will focus on:

  • methodological approaches to identifying what is important to patients with respect to disease burden and disease management; and
  • developing clinical outcome assessments to measure patient experience in clinical trials.

The FDA is seeking feedback, in particular, on (1) methods to identify what is important to patients; (2) best practices for eliciting information on which aspects of disease symptoms, signs, impacts, and other issues are important and meaningful to patients; (3) measuring symptoms, signs, impacts and other issues of a disease or condition in a meaningful way; and (4) selecting, developing, or modifying fit-for-purpose clinical outcome assessments to measure patient experience in clinical trials.[17] The FDA will use the feedback from this workshop in developing its next draft guidance on this topic.  

Patient-focused drug development carries important benefits for both patients and developers. For developers looking to design patient experience studies and develop commercial plans for leveraging those data, working closely with the FDA at the outset to ensure agency buy-in on the planned study design and methodology will be important, as with any clinical trial. Conducting such a study that yields a post-approval commercial marketing benefit may be even better, as seen with Rituxan Hycela, so working earlier than usual in drug development with a marketing team may prove worthwhile to understand the commercial opportunity and competitive space. 

Special thanks to Amanda White, a Goodwin 2018 summer associate, for assisting with the preparation of this alert.



[1] Patient-Focused Drug Development: Collecting Comprehensive and Representative Input; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders (June 2018) (Draft Guidance), available at https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM610442.pdf.
[2] 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1034 (2016).

[3] See FDA Plan for Issuance of Section 3002 Guidance (June 9, 2017), available at https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM563618.pdf.

[4] The FDA is required to work toward the goal of publishing a revised draft or final guidance within 18 months after the close of the public comment period on the draft guidance. See PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2018 Through 2022, 28-29, available at https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm511438.pdf.

[5] See Patient-Focused Drug Development: Disease Area Meetings Held in Fiscal Years 2013-2017, available at https://www.fda.gov/forindustry/userfees/prescriptiondruguserfee/ucm347317.htm.  Patient-focused drug development (PFDD) meetings were conducted by the FDA as part of the agency’s commitments under PDUFA V, but were not included as part of PDUFA VI.  Now, patient organizations have begun hosting their own externally-led PFDD meetings.

[6] Id.

[7] Draft Guidance at 2.

[8] Id. at 9.

[9] Id. at 5.

[10] Id.

[11] 21 U.S.C. § 360bbb–8c.

[12] See Patient-Focused Drug Development: Collecting Comprehensive and Representative Input; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders (June 2018) (herein “draft guidance”), available at https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM610442.pdf.

[13] See Vishal Bhatnagar, MD, Patient Experience in Oncology, FDA (Nov. 13, 2017).

[14] Rituxan Hycela (rituximab and hyaluronidase) Prescribing Information (June 2017).

[15] For U.S. Healthcare Professionals: Rituxan HYCELA™, at https://www.rituxanhycela.com/hcp.html (last visited Sept. 5, 2018).

[16] 83 Fed. Reg. 40,057 (Aug. 13, 2018).

[17] Id. at 40,058.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.